UDCA is used for the treatment of primary biliary cirrhosis, which activates PKC and MAPK signaling and anti-inflammatory hepatocyte pathways, as well as promoting bile HCO3− secretion to reduce cholestasis and reduce liver damage [39,43,44]. This evidence concerns the gene PRRT2 and cholestasis.